These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24758429)

  • 1. Enantioselective synthesis of PPAR (peroxisome proliferator-activated receptors) agonists and antagonists.
    Goya P; Perez-Fernandez R; Gonzalez-Muniz R; Elguero J
    Curr Top Med Chem; 2014; 14(10):1283-93. PubMed ID: 24758429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptor agonists with phenethylphenylphthalimide skeleton derived from thalidomide-related liver X receptor antagonists: relationship between absolute configuration and subtype selectivity.
    Motoshima K; Ishikawa M; Hashimoto Y; Sugita K
    Bioorg Med Chem; 2011 May; 19(10):3156-72. PubMed ID: 21514830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Biology-Based Exploration of Subtype-Selective Agonists for Peroxisome Proliferator-Activated Receptors.
    Miyachi H
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update about the crucial role of stereochemistry on the effects of Peroxisome Proliferator-Activated Receptor ligands.
    Laghezza A; Piemontese L; Tortorella P; Loiodice F
    Eur J Med Chem; 2019 Aug; 176():326-342. PubMed ID: 31112893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome.
    Tan CK; Zhuang Y; Wahli W
    Expert Opin Ther Targets; 2017 Mar; 21(3):333-348. PubMed ID: 28092722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking the peroxisome proliferator-activated receptor (PPAR): an overview.
    Ammazzalorso A; De Filippis B; Giampietro L; Amoroso R
    ChemMedChem; 2013 Oct; 8(10):1609-16. PubMed ID: 23939910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics.
    Dixit G; Prabhu A
    Exp Mol Pathol; 2022 Feb; 124():104723. PubMed ID: 34822814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptors and their relevance to dermatology.
    Friedmann PS; Cooper HL; Healy E
    Acta Derm Venereol; 2005; 85(3):194-202. PubMed ID: 16040401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationships of dimeric PPAR agonists.
    Sauerberg P; Mogensen JP; Jeppesen L; Svensson LA; Fleckner J; Nehlin J; Wulff EM; Pettersson I
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1497-500. PubMed ID: 15713415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A stereo-controlled synthesis of 2,4-dimethyl-4-hydroxy-16-phenylhexadecanoic acid 1,4-lactone and its PPAR activities.
    Ko J; Hwang H; Chin J; Hahn D; Lee J; Yang I; Shin K; Ham J; Kang H
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6017-9. PubMed ID: 20822906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoxazolyl-serine-based agonists of peroxisome proliferator-activated receptor: design, synthesis, and effects on cardiomyocyte differentiation.
    Wei ZL; Petukhov PA; Bizik F; Teixeira JC; Mercola M; Volpe EA; Glazer RI; Willson TM; Kozikowski AP
    J Am Chem Soc; 2004 Dec; 126(51):16714-5. PubMed ID: 15612696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists.
    Mahindroo N; Peng YH; Lin CH; Tan UK; Prakash E; Lien TW; Lu IL; Lee HJ; Hsu JT; Chen X; Liao CC; Lyu PC; Chao YS; Wu SY; Hsieh HP
    J Med Chem; 2006 Oct; 49(21):6421-4. PubMed ID: 17034149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.
    Merk D; Lamers C; Weber J; Flesch D; Gabler M; Proschak E; Schubert-Zsilavecz M
    Bioorg Med Chem; 2015 Feb; 23(3):499-514. PubMed ID: 25583100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome-proliferator-activated receptors and the control of levels of prostaglandin-endoperoxide synthase 2 by arachidonic acid in the bovine uterus.
    Sheldrick EL; Derecka K; Marshall E; Chin EC; Hodges L; Wathes DC; Abayasekara DR; Flint AP
    Biochem J; 2007 Aug; 406(1):175-83. PubMed ID: 17516915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Anticancer Potential of Peroxisome Proliferator-Activated Receptor Antagonists.
    De Lellis L; Cimini A; Veschi S; Benedetti E; Amoroso R; Cama A; Ammazzalorso A
    ChemMedChem; 2018 Feb; 13(3):209-219. PubMed ID: 29276815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, in vitro evaluation, and molecular modeling investigation of benzenesulfonimide peroxisome proliferator-activated receptors α antagonists.
    Ammazzalorso A; Carrieri A; Verginelli F; Bruno I; Carbonara G; D'Angelo A; De Filippis B; Fantacuzzi M; Florio R; Fracchiolla G; Giampietro L; Giancristofaro A; Maccallini C; Cama A; Amoroso R
    Eur J Med Chem; 2016 May; 114():191-200. PubMed ID: 26974385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: effect of introduction of fluorine at the linker part.
    Kasuga J; Oyama T; Hirakawa Y; Makishima M; Morikawa K; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4525-8. PubMed ID: 18662876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity landscape modeling of PPAR ligands with dual-activity difference maps.
    Méndez-Lucio O; Pérez-Villanueva J; Castillo R; Medina-Franco JL
    Bioorg Med Chem; 2012 Jun; 20(11):3523-32. PubMed ID: 22564380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.